Drug Profile
Research programme: therapeutics- Berg Pharma/Icahn School of Medicine at Mount Sinai
Latest Information Update: 24 Feb 2023
Price :
$50
*
At a glance
- Originator Berg Pharma; Icahn School of Medicine at Mount Sinai
- Developer Berg Pharma
- Class Antidementias; Antihyperglycaemics; Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Diabetes mellitus; Solid tumours
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA
- 28 Oct 2022 No recent reports of development identified for research development in Alzheimer's-disease in USA
- 28 Oct 2022 No recent reports of development identified for research development in Solid-tumours in USA